{"id":3687,"date":"2026-10-08T09:00:00","date_gmt":"2026-10-08T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3687"},"modified":"2026-10-09T16:10:09","modified_gmt":"2026-10-09T20:10:09","slug":"iberdomide-triplet-extends-progression-free-survival-in-myeloma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3687","title":{"rendered":"Iberdomide Triplet Extends Progression Free Survival in Myeloma"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Bristol Myers Squibb<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 confirmatory result (source-gap catch-up of 8 October announcement)<\/p>\n

Modality<\/strong><\/p>\n

Oral cereblon E3-ligase modulator combination (iberdomide + daratumumab + dexamethasone)<\/p>\n

Asset<\/strong><\/p>\n

Iberdomide (ZDd regimen)<\/p>\n

Target<\/strong><\/p>\n

Cereblon; IKZF1\/IKZF3 degradation<\/p>\n

Disease Area<\/strong><\/p>\n

Relapsed or refractory multiple myeloma<\/p>\n

Summary<\/h4>\n

Bristol Myers Squibb reported that the Phase 3 EXCALIBER-RRMM trial met its progression-free survival dual-primary endpoint for iberdomide plus subcutaneous daratumumab and dexamethasone (ZDd). Median progression-free survival was 42 months versus 20 months with daratumumab, bortezomib, and dexamethasone (DVd), hazard ratio 0.49, p<0.000001, in an 800-person trial. This October 8 event was missed in the previous package and is included as a source-gap catch-up.<\/p>\n

The randomized trial enrolled relapsed or refractory multiple myeloma as early as first relapse, assigning 400 participants to each arm. The announcement says the prespecified confirmatory PFS analysis followed an earlier minimal residual disease-negative complete response result used for accelerated approval of the ZDd regimen. Median follow-up was 23 months. Full data, including subgroup distributions, adverse events, dose intensity, and overall survival, have not yet been presented publicly; the company plans a medical-congress presentation.<\/p>\n

The comparison replaces bortezomib in a daratumumab and dexamethasone backbone with oral iberdomide. The reported hazard ratio indicates substantial separation within this trial and comparator, but the median estimates alone do not establish superiority over every contemporary anti-CD38 combination or cellular therapy sequence.<\/p>\n

Deep Analysis<\/h4>\n

Iberdomide is a cereblon E3-ligase modulator that drives degradation of IKZF1 and IKZF3, altering plasma-cell survival and immune effector programs. Its addition to an anti-CD38 antibody creates a mechanistically coherent triplet. Confirmatory PFS is particularly consequential after an accelerated approval linked to MRD-negative complete response; the new endpoint strengthens the clinical benefit case, subject to the prespecified analysis and data review.<\/p>\n

Interpretation A is that stronger cereblon modulation plus a tolerable antibody backbone has created a competitive, accessible option early in relapse. The randomized PFS result supports that within the studied setting. The strongest counterargument is comparator relevance: DVd is one standard regimen, but treatment choice now depends on lenalidomide exposure, anti-CD38 refractoriness, cytogenetic risk, frailty, route, and rapidly changing bispecific and CAR-T availability. Cross-trial numerical comparisons would be unsound.<\/p>\n

The public topline does not show overall survival, quality of life, discontinuations, infection burden, thromboembolism, or differential PFS in anti-CD38- or lenalidomide-exposed subsets. A 42-month Kaplan\u2013Meier median at 23 months median follow-up warrants inspection of numbers at risk and censoring. Prescriber and payer displacement depend on the full benefit-risk profile and relevance to the actual relapsed population, not the headline hazard ratio alone.<\/p>\n

Company and Product Background<\/h4>\n

Multiple myeloma is a malignant plasma-cell disease with repeated relapses and treatment sequencing shaped by prior exposure. Iberdomide is an oral cereblon E3-ligase modulator that induces IKZF1 and IKZF3 degradation. Daratumumab is an anti-CD38 antibody; bortezomib is a proteasome inhibitor. This report addresses the specific EXCALIBER-RRMM comparison.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Verified company-reported trial result: 800 randomized, median PFS 42 versus 20 months, HR 0.49, p<0.000001. The underlying patient-level dataset is not independently available in the release. Earlier MRD-negative complete response was a separate endpoint; it is not the new October 8 finding.<\/li>\n
  • Interpretation A: true regimen-level efficacy advantage over DVd. Interpretation B: a large but comparator-specific advantage with uncertain generalizability to current sequencing. Both are compatible with the release until full subgroup, safety, and OS data appear.<\/li>\n
  • Upgrade: prespecified full analysis with stable numbers at risk, consistent high-risk subgroup effects, manageable grade 3+ infection and discontinuation rates, quality-of-life support, and maturing OS. Downgrade: concentrated benefit in narrow subgroups, substantial exposure or infection tradeoffs, or weak performance after contemporary prior therapies.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a high-strength confirmatory clinical signal, with direction clearly favorable for PFS against DVd. The competitive question is narrower than the headline: how often the studied comparator remains the best alternative and whether the safety and survival profile sustain the advantage across increasingly pretreated myeloma.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 5 of 5. Signal Direction: positive for PFS versus DVd. Confidence in Facts: high for disclosed topline; full dataset pending. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Bristol Myers Squibb reported that the Phase 3 EXCALIBER-RRMM trial met its progression-free survival dual-primary endpoint for iberdomide plus subcutaneous daratumumab and dexamethasone (ZDd). Median progression-free survival was 42 months versus 20 months with…<\/p>\n","protected":false},"author":1,"featured_media":3692,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[101,1014,410,1013,353,30],"class_list":["post-3687","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-bristol-myers-squibb","tag-cereblon-e3-ligase-modulator","tag-daratumumab","tag-excaliber-rrmm","tag-iberdomide","tag-multiple-myeloma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3687","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3687"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3687\/revisions"}],"predecessor-version":[{"id":3693,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3687\/revisions\/3693"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3692"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3687"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3687"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3687"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}